Vertex Pharmaceuticals Inc (VRTX)

neg -3.85
Today's Range: 109.17 - 114.56 | VRTX Avg Daily Volume: 1,995,800
Last Update: 10/13/15 - 4:00 PM EDT
Volume: 1,671,551
YTD Performance: -4.67%
Open: $112.51
Previous Close: $113.25
52 Week Range: $96.43 - $143.45
Oustanding Shares: 244,655,527
Market Cap: 26,912,107,970
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 7
Moderate Buy 2 1 1 1
Hold 8 11 10 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.09 2.28 2.17 2.12
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -35.83
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-35.83 0.00 25.41
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-7.89% 8.14% 111.56%
Revenue -52.10 -0.59 -0.25
Net Income 0.00 -19.01 0.00
EPS 0.00 -23.43 0.00
Earnings for VRTX:
Revenue 0.58B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $-0.60 $-0.41 $-2.65 $3.65
Number of Analysts 2 2 2 2
High Estimate $-0.53 $-0.33 $-2.64 $4.98
Low Estimate $-0.67 $-0.48 $-2.66 $2.33
Prior Year $-0.57 $-0.73 $-2.93 $-2.65
Growth Rate (Year over Year) -5.26% 44.52% 9.56% 237.92%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Oct 02, 2015 | 7:58 AM EDT
VRTX was upgraded from Equal-weight to Overweight, Morgan Stanley said. Company is transitioning toward profitability and should outper...
Sep 14, 2015 | 8:10 AM EDT
VRTX was upgraded to Overweight, Barclays said. $150 price target. Expert feedback suggest upside for Orkambi.
There are some good buying ideas among these stocks.
Jul 06, 2015 | 7:38 AM EDT
Shares of VRTX now seen reaching $145, according to JMP Securities. Estimates also reduced, given lower realized pricing for Orkambi. O...
Sector may not be as bulletproof as we thought.
Apr 30, 2015 | 7:49 AM EDT
VRTX estimates were raised through 2016, Leerink Partners said. Orkambi should drive near-term growth. Outperform rating and new $150 p...
Biotech companies are saying, "I do."
Teva bid highlights M&A action in health care sector.
Teva bid highlights M&A action in health care sector.

Columnist Conversations

Would certainly be taking notes on Hillary's comments regarding drug companies ahead of tomorrow's session...
The Biotech iShares (IBB) dropped sharply last month and then began consolidating in triangle pattern. The dro...
You have to be positioned to be lucky. Well done, Bob.
Sometimes it's better to be lucky than good! As mentioned below, we added the SNDK nov 62.5 calls today on so...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.